Navigation Links
GeneLink Marketing Efforts Poised to Show Results
Date:11/21/2011

ORLANDO, Fla., Nov. 21, 2011 /PRNewswire/ -- GeneLink, Inc. (OTCBB: GNLK.OB, "the Company," or "GeneLink"), a leading consumer genomics biotech company, reported financial results for the quarter ended September 30th, 2011.

Bernard L. Kasten, M.D., GeneLink's Chairman and CEO stated, "From a business development potential, the third quarter has been the most exciting period in the history of the Company.  The Company continues to make progress towards the launch of two exciting new personalized consumer product lines.  These include a large scale direct-to-consumer initiative featuring a new brand being launched with Robert B. Trussell, Jr., Founder and Vice-Chairman of Tempur-Pedic, Inc.  In addition to this opportunity, in early 2012 we will launch a specialized exclusive product line for aesthetic physicians under GeneLink's Dermagenetics® brand.  We have already developed a unique line of products and are working with world class marketing partners for our initial launch into this arena."

Dr. Kasten added, "Importantly, the third quarter was most notable for our announced pending sale of GeneWize, our direct selling subsidiary, to Capsalus Corp. (OTCBB: WELL).  The definitive agreements which we executed on October 13, 2011 provide us with a motivated and experienced marketing partner in multiple direct selling channels.  Once we receive the necessary GeneLink's shareholder approval for the sale of GeneWize to Capsalus, we will be especially pleased to have positioned GeneWize and its marketing affiliates for success." 

Financial Results for the three months ended September 30, 2011 , are comprised mainly of sales from the Company's GeneWize direct selling subsidiary, and  compared to 2010 results as follows:

  • Net sales were $1,069,760, compared to $1,877,136 in the prior year.
  • Gross profit margins decreased to 59%, compared to 66.8% in the prior year.
  • Operating losses were $880,009 compared to $822,970 in the prior year.  

John A. Webb, GeneLink's, CFO added:  "Financially, the pending sale of GeneWize has provided an attractive way to expand our operating infrastructure in support of our distribution partners.  In each relationship, our partners will be selling services and products purchased from GeneLink.  This business model is designed to allow GeneLink to sell more products, at stronger margins, with reduced overhead. It also allows management and our renowned Scientific Advisory Board to extend GeneLink's position as a consumer genomics leader through focused efforts in developing new and innovative assessments, products, and customization methodologies."

Dr. Kasten concluded, "The short term future of GeneLink is more promising than at any time in the history of this Company.  We at GeneLink intend to remain a leader in the burgeoning field of personalized consumer genetics for years to come."

About GeneLink Biosciences, Inc.:

GeneLink is a 17-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA assessments linked to personalized nutrition, skincare and wellness applications and products.  For more information visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

 

                                                                                   


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
2. GeneLink Reports Second Quarter 2011 Results
3. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
4. GeneLink Reports Denial of Appeal
5. GeneLink Reports 2010 Results
6. GeneLink Announces New Licensing Partner
7. GeneLink Reports Third Quarter Results
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. GeneLink Announces HelixLife Private Label Distribution Agreement
10. GeneLink Reports First Quarter Gains
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
(Date:2/21/2017)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... ended December 31, 2016. SQI is a ... that develops and commercializes proprietary technologies and products for advanced ... ... achieved in fiscal 2016," said Andrew Morris , SQI,s ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution provider ... executive team to lead the development and commercialization of its Cancer Information Data ... diagnosis and treatment of cancer. The CIDT addresses the need for curated and ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... transformative design and manufacturing solutions for original equipment manufacturers (OEMs) , today announced ... marks Creation Technologies’ third consecutive year winning in its category of electronics manufacturing ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):